{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040936","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.860479+00:00","generated_at":"2026-06-11T19:23:18.910435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvalent Q2 net loss $29.1M; cash $431.2M; NVL-655 data expected Q4 2023","bullets":["Net loss $29.1M ($0.51/share); R&D $25.9M, G&A $8.1M for Q2 2023.","Cash, cash equivalents and marketable securities $431.2M as of June 30, 2023; runway into H2 2025.","Preliminary dose-escalation data for NVL-655 from ALKOVE-1 trial expected at medical meeting in Q4 2023.","NVL-520 ARROS-1 trial progressing toward RP2D; NVL-330 HER2 inhibitor advancing through IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040936","json":"https://secwatch.observer/filing/0000950170-23-040936.json","markdown":"https://secwatch.observer/filing/0000950170-23-040936.md","text":"https://secwatch.observer/filing/0000950170-23-040936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023040936/0000950170-23-040936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023040936/nuvl-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:23:18.910435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f682e7ecd5a0b8f60db2f3c3a323fd95ae7f099b","claim":"Nuvalent, Inc. reported second quarter 2023 results: net income $29.1 million, or $0.51 per share.","evidence_excerpt":"Net loss for the second quarter of 2023 was $29.1 million, or $0.51 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023040936/0000950170-23-040936-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Net income","value":"$29.1 million, or $0.51 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}